|
Sign In to gain access to subscriptions and/or personal tools.
|
Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease
Bertram Pitt
Division of Cardiology, The University of Michigan, USA, bpitt{at}umich.edu
Charles T Stier, Jr
Department of Pharmacology, New York Medical College, USA
Sanjay Rajagopalan
Division of Cardiology, The University of Michigan, USA
Mineralocorticoid receptor (MR) blockade is effective in reducing total mortality and the incidence of heart failure in patients with systolic left ventricular dysfunction (SLVD) associated with chronic heart failure or post myocardial infarction.
Pre-clinical and clinical studies in SLVD have shown that MR blockade reduces sudden cardiac death, left ventricular remodelling, left ventricular hypertrophy, endothelial dysfunction, autonomic imbalance, renal dysfunction and improves fibrinolysis.
While MR blockade promotes sodium excretion and the combination of an angiotensin-converting enzyme inhibitor and a MR blocker have been shown to be more effective than either alone in causing natriuresis, it is unlikely that their beneficial effects can be explained solely on this basis.
Aldosterone has been shown to have a number of adverse effects, including activation of other neurohumeral mediators, stimulation of active reactive oxygen species (ROS), activation of the NF- β and AP-1 signalling pathways, vascular inflammation and fibrosis, myocardial hypertrophy, autonomic imbalance, and a decrease in fibrinolysis. MR blockade is, however, effective both in situations with and without an increase in serum aldosterone level, since the MR can be occupied and activated by cortisol as well as by aldosterone.
In view of these mechanisms, MR blockade may play an important role not only on SLVD, but also in essential hypertension with normal systolic function, diastolic heart failure, valvular heart disease, vascular stiffening with ageing, progression of renal disease, and diabetes mellitus. This hypothesis will, however, require further prospective evaluation.
Key Words: aldosterone • cortisol • systolic left ventricular dysfunction • heart failure • myocardial infarction
References
- Pitt B., Zannad F., Remme W. et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709.[Abstract/Free Full Text]
- Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.[Abstract/Free Full Text]
- van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71:21A-28A.[CrossRef][Medline]
[Order article via Infotrieve]
- Muller J. Spironolactone in the management of congestive cardiac failure: a review. Clin Ther 1986;9:63-76.[Web of Science][Medline]
[Order article via Infotrieve]
- Cody RJ, Pitt B., Perez A., Bettman R. The benefit of spironolactone in the RALES Trial is not primarily due to a diuretic effect.J Am Coll Cardiol 2000;35:212A.
- Weber KT Aldosterone in congestive heart failure. N Engl J Med 2000;345:1689-97.[CrossRef][Web of Science]
- Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000;102:2700-06.[Abstract/Free Full Text]
- Young M., Head G., Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269:E657-E662.[Web of Science][Medline]
[Order article via Infotrieve]
- MacFadyen RJ, Barr CS, Struthers ADAldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.[Abstract/Free Full Text]
- Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-5.[Abstract/Free Full Text]
- Yee KM, Struthers AD Aldosterone blunts the baroreflex response in man. Clin Sci (Lond) 1998;95:687-92.[Medline]
[Order article via Infotrieve]
- Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85:33644.
- Brown NJ, Nakamura S., Ma L. et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000;58:1219-27.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Farquharson CA, Struthers AD Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.[Abstract/Free Full Text]
- Funder JW, Pearce PT, Smith R., Campbell J. Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 1989;125:2224-6.[Abstract/Free Full Text]
- Lombes M., Oblin ME, Gasc JM, Baulieu EE, Farman N., Bonvalet JP Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71:503-10.[Abstract/Free Full Text]
- Hatakeyama H., Miyamori I., Takeda Y., Yamamoto H., Mabuchi H. The expression of steroidogenic enzyme genes in human vascular cells. Biochem Mol Biol Int 1996;40:639-45.[Web of Science][Medline]
[Order article via Infotrieve]
- Takeda Y., Miyamori I., Inaba S. et al.Vascular aldosterone in genetically hypertensive rats. Hypertension 1997;29:45-8.[Abstract/Free Full Text]
- Silvestre JS, Robert V., Heymes C. et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. JBiol Chem 1998;273:4883-91.[Abstract/Free Full Text]
- Kayes-Wandover KM, White PC Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000;85:2519-25.[Abstract/Free Full Text]
- Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.[Abstract/Free Full Text]
- Pitt B. `Escape` of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovascular Drugs & Therapy 1995;9:145-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- StruthersAD Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.[CrossRef][Medline]
[Order article via Infotrieve]
- McKelvie RS,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators [see comments]. Circulation 1999;100:1056-64.[Abstract/Free Full Text]
- Cicoira M., Zanolla L., Rossi A. et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37:1808-12.[Abstract/Free Full Text]
- Quinn S., Williams G. Regulation of aldosterone secretion. Annu Rev Physiol 1988;50:409-26.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Aguilera G. Factors controlling steroid biosynthesis in the zona glomerulosa of the adrenal. J Steroid Biochem Mol Biol 1993;45:147-51.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rossi GP, Belloni AS, Nussdorfer GG, Pessina AC Endothelin-1 and the adrenal gland. J Cardiovascular Pharmacol 2000;35:S17-S20.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Guillon G., Trueba M., Joubert D. et al. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology 1995;136:1285-95.[Abstract]
- Okubo S., Niimura F., Nishimura H. et al.Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997;99: 855-60.[Web of Science][Medline]
[Order article via Infotrieve]
- Harada E.,Yoshimura M.,Yasue H. et al.Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-9.[Abstract/Free Full Text]
- Park JB, Schiffrin EL ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats.Hypertension 2001;37:1444-9.[Abstract/Free Full Text]
- Barr CS, Lang CC, Hanson J.,Arnott M., Kennedy N., Struthers AD Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76: 1259-65.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Liu YJ, Nakagawa Y.,Toya K. et al. Effects of spironolactone on systolic blood pressure in experimental diabetic rats. Kidney Int 2000;57:2064-71.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pitt B., Reichek N., Metscher B. et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy for essential hypertension and left ventricular hypertrophy: The 4E Study. In: American College of Cardiology. Atlanta, GA; Circulation 2002: in press.
- Heiniger CD, Kostadinova RM, Rochat MK et al. Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1. Faseb J 2003;17:917-19.[Abstract/Free Full Text]
- Rocha R., Chander PN, Khanna K., Zuckerman A., Stier CT, Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-8.[Abstract/Free Full Text]
- Rocha R., Chander PN, Zuckerman A., Stier CT, Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats.Hypertension 1999;33:232-7.[Abstract/Free Full Text]
- Luft FC Mechanisms and cardiovascular damage in hypertension. Hypertension 2001;37:594-8.[Abstract/Free Full Text]
- Stier Jr CT, Zuckerman A., Harashima H., Chander P. Antioxidants reduce aldosterone-induced renal vascular injury in stroke-prone spontaneously hypertensive rats. 18th Scientific Meeting of the International Society of Hypertension, Chicago, IL. 2000;5:5-75.
- Rajagopalan S., Duquaine D., King S., Pitt B., Patel P. Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis. Circulation 2002;105:2212-16.[Abstract/Free Full Text]
- Bauersachs J., Heck M., Fraccarollo D. et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction; Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002; 39:351-8.[Abstract/Free Full Text]
- Natarajan R., Lanting L., Bai W., Bravo EL, Nadler J.The role of 1997;61:47-53. nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells. J Steroid Biochem Mol Biol
- Hanke CJ, O'Brien T., Pritchard KA, Campbell WB Inhibition of adrenal cell al dosterone synthesis by endogenous nitric oxide release. Hypertension 2000;35:324-8.[Abstract/Free Full Text]
- Usui M., Ichiki T., Katoh M., Egashira K., Takeshita A. Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 1998;32:527-33.[Abstract/Free Full Text]
- Takeda Y., Yoneda T., Demura M., Furukawa K., Miyamori I., Mabuchi H. Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats.JHypertens 2001;19:635-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Trolliet MR, Rudd MA, Loscalzo J. Oxidative stress and renal dysfunction in salt-sensitive hypertension. Kidney Blood Press Res 2001;24:116-23.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ni Z., Vaziri ND Effect of salt loading on nitric oxide synthase expression in normotensive rats. Am J Hypertens 2001; 14:155-63.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lim PO, Farquharson CA, Shiels P., Jung RT, Struthers AD, MacDonald TM Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension 2001;37:856-61.[Abstract/Free Full Text]
- Blasi ER, Friedrich GE, De Ciechi PA et al.Aldosterone/saltinduced myocardial injury: a vascular inflammatory disease. Am J Hypertens 2001;14:8A-9A.
- Sun Y., Zhang J., Zhang JQ, Ramires FJ Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000;35:1078-84.[Abstract/Free Full Text]
- Dorrance AM, Osborn HL, Grekin R., Webb RC Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 2001;281:R944-R950.[Abstract/Free Full Text]
- Brilla CG, Pick R.,Tan LB, Janicki JS,Weber KT Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64.[Abstract/Free Full Text]
- Weber KT Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000;15:264-72.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sawathiparnich P., Kumar S., Vaughan DE, Brown NJ Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002;87:448-52.[Abstract/Free Full Text]
- Brown NJ, Kim KS, Chen YQ et al. Synergistic effect of adrenal steroids and angiotensin II on plaminogen activator-1 production. J Clin Endocrinology Metab 2000;95:336-44.
- Vaughan DE Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol 2001;87:18C-24C.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Nayier W. The inotropic action of d-aldosterone on papillary muscles isolated from monkeys. J Pharmacol Exp Ther 1965;148:215-17.[Abstract/Free Full Text]
- Yee KM, Pringle SD, Struthers AD Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-07.[Abstract/Free Full Text]
- Chowdhary S., Vaile JC, Fletcher J., Ross HF, Coote JH, Townend JN Nitric oxide and cardiac autonomic control in humans. Hypertension 2000;36:264-9.[Abstract/Free Full Text]
- Schwarz P., Diem R., Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 1995;77:841-8.[Abstract/Free Full Text]
- Silvestre J-S., Heymes C., Oubenaissa A. et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701.[Abstract/Free Full Text]
- Hayashi M.,TsutamotoT.,WadaA. et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003:107:2559-65.[Abstract/Free Full Text]
- Modena MG,Aveta P., Menozzi A., Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141:41-6.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kasama S., Toyama T., Kumakura H. et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81.[Abstract/Free Full Text]
- Flack JM, Oparil S., Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-55.[Abstract/Free Full Text]
- White WB, Duprez D., St Hillaire R. et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6.[Abstract/Free Full Text]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 3,
164-168 (2003)
DOI: 10.3317/jraas.2003.025
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Kasama, T. Toyama, H. Sumino, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Additive Effects of Spironolactone and Candesartan on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Congestive Heart Failure
J. Nucl. Med.,
December 1, 2007;
48(12):
1993 - 2000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Guder, J. Bauersachs, S. Frantz, D. Weismann, B. Allolio, G. Ertl, C. E. Angermann, and S. Stork
Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure
Circulation,
April 3, 2007;
115(13):
1754 - 1761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Pitt and B. Pitt
Aldosterone, ion channels, and sudden death: another piece of the circle?
Am J Physiol Heart Circ Physiol,
June 1, 2006;
290(6):
H2176 - H2177.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Perrier, S. Richard, Y. Sainte-Marie, B. C. Rossier, F. Jaisser, E. Hummler, and J.-P. Benitah
A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice
J. Physiol.,
November 15, 2005;
569(1):
153 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Kuster, E. Kotlyar, M. K. Rude, D. A. Siwik, R. Liao, W. S. Colucci, and F. Sam
Mineralocorticoid Receptor Inhibition Ameliorates the Transition to Myocardial Failure and Decreases Oxidative Stress and Inflammation in Mice With Chronic Pressure Overload
Circulation,
February 1, 2005;
111(4):
420 - 427.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
